A Shrewd Ingenious Approach of Oral Drug Delivery of Insulin for the Amelioration of Diabetic Patients with Better Therapeutic Outcomes

Gannoji Sainath Chary *

St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.

Basani Pavithra Reddy

St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.

Rasuri Charishma

St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.

Asra Tabassum

St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.

Samreen Afroz

Department of Pharmacy Practice, St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.

*Author to whom correspondence should be addressed.


Abstract

Since 1922, insulin has saved the lives of countless people. However, the difficulties of subcutaneous administration, the need for frequent glucose self-monitoring, and the non-physiological action profiles of insulin prompted many medical professionals and patients to ask for non-injectable insulin delivery methods.

Alternative administration techniques without the need for an injection are widely desired. Since it is simple for patients and doesn't involve injection, the oral route is the preferred way to provide medication. The gastrointestinal stability of protein therapeutics is one of several major obstacles to the effective development of oral protein medication formulations.

An oral formulation for a protein and peptide medication must maintain the medication's structural integrity, guard against proteolysis, and enable bloodstream absorption. To satisfy these needs, a number of strategies for oral protein administration have been suggested.

When assessing the potential of insulin-loaded nanoparticles, toxicity is a crucial element to take into account. Nanoparticles must be checked to make sure they don't have any negative impacts or even harm the intestinal epithelium because they are designed to interact with 527 Oral Insulin Delivery.

Oral insulin delivery has been an interesting and promising research field that promises to revolutionize the way diabetes mellitus is treated.

Overall, the success of oral insulin hinges on the ability to produce insulin both effectively in a price-conscious pharmaceutical market and in adequate amounts for oral delivery. It is evident that more effort needs to be done to bring the first insulin oral delivery system to the market. Pharmaceutical companies are leading the charge in creating a system to give insulin orally. Successfully addressing the problems will usher in a new era of diabetes care.

Keywords: Insulin, oral drug delivery, type 1 diabetes mellitus, protein peptide therapeutic approach


How to Cite

Chary , Gannoji Sainath, Basani Pavithra Reddy, Rasuri Charishma, Asra Tabassum, and Samreen Afroz. 2023. “A Shrewd Ingenious Approach of Oral Drug Delivery of Insulin for the Amelioration of Diabetic Patients With Better Therapeutic Outcomes”. Asian Journal of Research and Reports in Endocrinology 6 (1):141-50. https://journalajrre.com/index.php/AJRRE/article/view/78.


References

Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs. 2007;16(16): 1002–7.

Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304–9.

Berger M. Oral insulin 1922-1992: The history of continuous ambition and failure. In Frontiers in insulin pharmacology. Edited by: Berger M, Gries FA. Germany: Thieme Publishing Group. 1993;144-8.

Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33:240-245.

Al-Tabakha MM, Arida AI. Recent challenges in insulin delivery systems: A review. Indian J Pharm Sci. 2008;70:278.

Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144(7):465–74.

Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol. 2009;3(3):568–84.

Zijlstra E, Heinemann L, Plum-Mörschel L. Oral Insulin Reloaded. J. Diabetes Sci. Technol. 2014;8(3):458–465.

DOI: 10.1177/1932296814529988

Beals JM, Kovach P. Crommelin DJ, Sindelar RD. Insulin. In: Pharmaceutical biotechnology. Netherlands: Harwood Academic Publishers. 1997;229–39.

Hoffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinetic. 1997;33(4):285–301.

Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33: 240-5.

Beals JM, Kovach P. Crommelin DJ, Sindelar RD. Insulin. In: Pharmaceutical biotechnology. Netherlands: Harwood Academic Publishers. 1997;229–39.

Li J, Yang L, Ferguson SM, Hudson TJ, Watanabe S, Katsuma M, Fix JA. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS PharmSciTech. 2002;3(4):33.

Katsuma M, Watanabe S, Kawai H, Takemura S, Sako K. Effects of absorption promoters on insulin absorption through colon-targeted delivery. Int J Pharm. 2006;307(2):156–62.

Hosny EA, Al-Shora HI, Elmazar MM. Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. Int J Pharm. 2002;237(1-2):71–6.

Whitehead K, Shen Z, Mitragotri S. Oral delivery of macromolecules using intestinal patches: Applications for insulin delivery. J Control Release. 2004;98(1):37–45.

Saadine JB, Cadwell B, Gregg EB et al: Improvement in diabetes processes of care and intermediate outcomes: United States 1988-2002. Ann Intern Med 2006;144:465-474.

Heinemann L, Jacques Y: Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol. 2009;3:568-584.

Wajchenberg BL: Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.

Skyler JS, Krischer JP, Wolfsdorf J, et al: Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005;28:1353-1357.

Bergerot I, Arreaza GA, Cameron MJ, et al. Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes. 1999;48:1720-1729.

Stratton IM, Adler Al, Neil HAW, et al: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;405-412.

Hossain S, Chowdhury EH, Akaike T. Nanoparticles and toxicity in therapeutic delivery: the ongoing debate. Ther Deliv. 2011;2(2):125–32.

Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target. 2004;12(2):65–70.

Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–95.

Gowthamarajan K, Kulkarni G. Oral insulin: Fact or fiction? Possibilities of achieving oral delivery for insulin. Resonance. 2003; 8(5):38–46.

Saadine JB, Cadwell B, Gregg EB, et al: Improvement in diabetes processes of care and intermediate outcomes: United States 1988-2002. Ann Intern Med. 2006;144:465-474.

Fonte P, Araújo F, Reis S, Sarmento B. Oral insulin delivery: How far are we?. Journal of Diabetes Science and Technology. 2013;7(2):520-31.